Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Recruiting
Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mamm... Read More
Gender:
FEMALE
Ages:
Between 30 years and 74 years
Trial Updated:
06/20/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +10 locations
Conditions: Breast Cancer Screening, Breast Carcinoma in Situ, Breast Cancer
Genetic and Metabolic Disease in Children
Recruiting
This is a prospective, non-randomized, non-blinded observational study. The overarching goal is to discover new disease-associated genes in children, while establishing a specific focus on disorders where molecular characterization is most likely to lead to novel therapies. This study will merge detailed phenotypic characterization of patients presenting to the Pediatric Genetics and Metabolism Division in the Department of Pediatrics/Children's Medical Center at Dallas and collaborating clinics... Read More
Gender:
ALL
Ages:
1 day and above
Trial Updated:
06/20/2025
Locations: Children's Medical Center at Dallas, Dallas, Texas
Conditions: Genetic Diseases, Metabolic Diseases
MSC EVs in Dystrophic Epidermolysis Bullosa
Recruiting
INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND RATIONALE: The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with Epidermolysis Bullosa (EB). STUDY DESIGN: This is a phase 1/2A, randomized, multi-center, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with EB.
Gender:
ALL
Ages:
6 months and above
Trial Updated:
06/20/2025
Locations: Phoenix Children's Hospital, Phoenix, Arizona +2 locations
Conditions: Dystrophic Epidermolysis Bullosa
Dietary Fiber Effects on the Microbiome and Satiety
Recruiting
Strong evidence supports the association between high fiber (HiFi) diets (e.g. legumes, nuts, vegetables) and a reduced risk for chronic conditions such as cardiovascular disease (CVD), type 2 diabetes and some forms of cancer. However, the current U.S. average consumption of dietary fiber of 17g/day is significantly below the recommendation level of 25g/d for women and 38g/d for men. Furthermore, fiber fermentation to produce short chain fatty acid (SCFA) products and alterations in microbial c... Read More
Gender:
ALL
Ages:
Between 20 years and 55 years
Trial Updated:
06/20/2025
Locations: University of Missouri-Columbia, Columbia, Missouri
Conditions: Dietary Fiber
Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study
Recruiting
The proportion of noncardiac surgeries performed as same-day surgery is increasing worldwide, with more complex surgeries being performed on higher risk patients in the outpatient setting. Little is known on the risk factors, incidence and prognosis of patients undergoing same-day noncardiac surgery. The main objective of this study is to inform on the incidence and risk factors of cardiovascular and other adverse events after same-day surgery and to develop risk prediction tools to better infor... Read More
Gender:
ALL
Ages:
45 years and above
Trial Updated:
06/20/2025
Locations: Wake Forest Baptist Medical Centre, Winston-Salem, North Carolina +15 locations
Conditions: Preoperative Care, Surgery--Complications, Myocardial Infarction
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Recruiting
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study, we aim to use RIC followed by matched related/unrelated donor, 7/8 matched related/unrelated donor, or haploidentical donor peripheral blood stem cell transplantation. Standard strategies to control the alloreactivity following HCT util... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/20/2025
Locations: Stanford University, Stanford, California
Conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Recruiting
The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease, Rosai-Dorfman Disease
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
Recruiting
The main purpose of this study is to continue to see how vonsetamig works in the body and to monitor the outcomes after kidney transplant for participants previously treated in the R5459-RT-1944 study (NCT05092347). No study drug will be given during this study.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/20/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California +8 locations
Conditions: Chronic Kidney Disease (CKD)
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Recruiting
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment. Substudies will evaluate the safety and tolerability of 4D-150 contralateral eye dosing and characterize vector shedding.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/20/2025
Locations: Barnet Delaney Perkins Eye Center, Phoenix, Arizona +23 locations
Conditions: Neovascular (Wet) Age-Related Macular Degeneration
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
Recruiting
The main goal of this current study is to develop and optimize methods for increasing access to, uptake of, and engagement in MAT (Medication Assisted Treatment) among communities of color.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Mount Aery Baptist Church, Bridgeport, Connecticut +7 locations
Conditions: Substance Use, Mental Health Issue, Opioid Use, Medication Assisted Treatment
Dropless Pars Plana Vitrectomy Study
Recruiting
To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy for retinal detachment.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/20/2025
Locations: Massachusetts Eye and Ear, Boston, Massachusetts
Conditions: Rhegmatogenous Retinal Detachment
ViDES Trial (Vitamin D Extra Supplementation)
Recruiting
The objective of the study is to compare supplementation with vitamin D at 800 IU/day to usual care for the first 28 days after birth with respect to 25 (OH) vitamin D levels and indicators of likely or plausible effects of vitamin D supplementation on the function or structure of the lung, bones, immune system, and brain in extremely premature (EP) infants who are \<28 weeks gestational age (GA) or \<1000 grams of birth weight (BW). The study results will be analyzed as intention to treat Bayes... Read More
Gender:
ALL
Ages:
Between 24 hours and 96 hours
Trial Updated:
06/20/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Vitamin D Deficiency